fulvestrant + neratinib + paclitaxel

This is a combination regimen consisting of fulvestrant, neratinib, and paclitaxel, used primarily in the treatment of hormone receptor-positive (HR+), HER2-positive or HER2-mutant metastatic breast cancer. - **Fulvestrant** is a selective estrogen receptor degrader (SERD) that binds to and accelerates degradation of the estrogen receptor, blocking estrogen signaling in tumor cells. - **Neratinib** is an oral irreversible pan-HER tyrosine kinase inhibitor targeting HER1 (EGFR), HER2, and HER4 receptors; it blocks downstream signaling pathways involved in cell proliferation and survival. - **Paclitaxel** is a microtubule-stabilizing chemotherapeutic agent that inhibits cell division by promoting tubulin polymerization and preventing microtubule disassembly. The rationale for this combination arises from evidence that dual blockade of both the estrogen receptor pathway (by fulvestrant) and the ErbB/HER family pathway (by neratinib) can overcome compensatory crosstalk between these pathways—an important resistance mechanism in HR+/HER2+ breast cancers. Paclitaxel adds cytotoxic activity to further suppress tumor growth[3][4][6]. This regimen has been studied particularly in patients with heavily pretreated metastatic breast cancer who have progressed on prior therapies[3].